Drugs / AZD2516
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT01148095 | Jun → Jul 2010 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00972049 | Sep → Dec 2009 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00892944 | Apr → Oct 2009 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00754715 | Sep → Nov 2008 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01154634 | May → Sep 2010 | gastroesophageal reflux disease | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD2516 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01148095 ↗ |
| Action | Inhibit | “Metabotropic glutamate receptor 5 negative allosteric modulator” CHEMBL3545346 ↗ |
| Route | Oral | “Solution administered once orally” NCT00754715 ↗ |
| Target | GRM5 | “Metabotropic glutamate receptor 5 negative allosteric modulator” CHEMBL3545346 ↗ |